A coated balloon and a method for preparing the same
The stable connection of paclitaxel through the polyglutamic acid polymer layer and the connecting factor solves the problem of premature drug fall off in the drug-coated balloon, achieves stable release and precise drug delivery, and improves the therapeutic effect.
Patent Information
- Application Number
- CN202411074162.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-07
AI Technical Summary
The poor firmness of the drug coating in the drug-coated balloon causes premature falloff of the drug, affecting the treatment effect, and the hydrophilic coating leads to low drug utilization, making it difficult to achieve accurate drug administration.
The polyglutamic acid polymer layer is used to stably connect paclitaxel to form an ester group to ensure the stability of the drug in the coating, and enhance the tight connection between the coating and the balloon through heat treatment and immersion techniques.
The stable release and precise drug delivery are achieved, the therapeutic effect is improved, the adhesion of the coating and the bioavailability of the drug are enhanced.
Smart Images

Figure CN118576784B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of balloons, and in particular to a coated balloon and a preparation method thereof. Background Art
[0002] Drug coated balloon (DCB) technology is a new type of coronary interventional treatment technology in recent years, and was first used to treat in-stent restenosis. The surface of DCB is evenly coated with anti-cell proliferation drugs (paclitaxel or rapamycin). As the balloon expands, the drugs quickly enter the vascular wall tissue and can remain for 7-14 days, playing a role in treating in-stent restenosis without having to put in a new stent.
[0003] However, in recent years, it has been found that most drugs coated on drug-coated balloons are fat-soluble. In order to improve the bioavailability of the drug coating and increase the utilization rate of the drug coating, water-soluble substances are often carried. However, the hydrophilic coating can easily lead to the loss of therapeutic drugs, which ultimately causes the drugs to fall off prematurely from the coating on the surface of the balloon, causing the drug coating to be lost before it reaches the site of action. In addition, the coating on the surface of the balloon needs to have good contact with the blood vessel wall to maximize the bioavailability of the drugs in the coating. However, the poor firmness of the drug coating in the drug-coated balloon in the prior art is also an important reason why the drugs in the coating cannot be accurately administered. All of these reasons will result in poor treatment effects on patients. Summary of the invention
[0004] In order to solve the above technical problems, the present invention provides a coated balloon and a preparation method thereof. The coating on the balloon of the present invention can firstly be tightly connected to the surface of the balloon to achieve precise drug delivery. Secondly, the therapeutic drug paclitaxel can be stably connected to the coating, thereby preventing paclitaxel from falling off from the coating prematurely, so that the coating can achieve stable release of the paclitaxel drug.
[0005] The present invention provides a coated balloon, wherein a coating is loaded on the surface of the balloon, wherein the coating comprises a polyglutamic acid polymer layer, and a linking factor connects paclitaxel to the polyglutamic acid polymer layer;
[0006] The structural formula of the linking factor is as follows:
[0007] , where Br is bromine, O is oxygen, H is hydrogen, N is nitrogen, and OH is hydroxyl;
[0008] The polyglutamic acid polymer layer is connected to the surface of the balloon.
[0009] Furthermore, the polyglutamic acid polymer layer includes polyglutamic acid, and the linking factor and the polyglutamic acid form an ester group, so that the linking factor is connected to the polyglutamic acid polymer layer;
[0010] The linker and paclitaxel form an ester group, so that the linker is linked to paclitaxel.
[0011] The present invention also provides a method for preparing the coated balloon, the method comprising:
[0012] A connecting factor is prepared, the connecting factor undergoes an esterification reaction with polyglutamic acid in a polyglutamic acid polymer layer to obtain an intermediate product, the intermediate product undergoes an esterification reaction with paclitaxel to obtain a coating substance (PGlu-FC-PTX), the coating substance is dissolved to obtain a coating solution, the balloon is immersed in the coating solution at least once, and heat-treated to obtain a coated balloon (PGlu-FC-PTX@CB).
[0013] Furthermore, the mass concentration of the coating substance in the coating solution is 10%.
[0014] Furthermore, the method for preparing the coating solution includes dispersing the coating material in physiological saline.
[0015] Furthermore, the heat treatment temperature is 45°C-55°C, and the heat treatment time is 50min-70min.
[0016] Furthermore, the soaking time is 50s-70s.
[0017] Further, the balloon is immersed in the coating solution twice, the first immersion time is 50s-70s, and the second immersion time is 10s-20s, and heat treatment is performed after each immersion.
[0018] Furthermore, the preparation method of the ligation factor comprises:
[0019] Step S1: 5-(Hydroxymethyl)furan-2-acetaldehyde and diethyl ether are mixed, and the solution is cooled to -30°C after mixing, and 3M diethyl ether solution of methyl magnesium bromide is added, and the mixture is heated to room temperature for reaction, and the mixture is cooled to 0°C, and ammonium chloride solution is added for quenching to obtain compound 1;
[0020] Step S2: Compound 1, triethylamine and dichloromethane are mixed, and the mixed solution is cooled to 0°C after mixing; dichloromethane containing α-bromoisobutyl bromide is then added dropwise, and after the addition is completed, the mixed solution is returned to room temperature and allowed to stand for reaction, and the reacted substance is added to ice water, filtered, washed, concentrated, and purified to obtain Compound 2;
[0021] Step S3: Compound 2, N-(2-hydroxyethyl)maleimide and chloroform are mixed and reacted to separate the target product to obtain a linking factor.
[0022] Furthermore, after the 5-(hydroxymethyl)furan-2-acetaldehyde and diethyl ether are mixed, the mass concentration of 5-(hydroxymethyl)furan-2-acetaldehyde is 6.92 g / 300 mL.
[0023] Furthermore, based on volume, the volume ratio of the methyl magnesium bromide, 3M ether solution, ether, and ammonium chloride solution is 42:300:200.
[0024] Furthermore, the mass concentration of the ammonium chloride solution is 9%-11%.
[0025] Furthermore, the preparation method of the ammonium chloride solution includes dispersing ammonium chloride in deionized water.
[0026] Furthermore, the reaction time in step S1 is 11h-13h.
[0027] Furthermore, the room temperature is 18°C-26°C.
[0028] Furthermore, in step S1, stirring can be used during the reaction process to promote a full reaction between the substances.
[0029] Furthermore, in step S2, after the compound 1, triethylamine and dichloromethane are mixed, the mass concentration of the compound 1 is 2.74 g / 153 mL.
[0030] Furthermore, in step S2, the volume ratio of triethylamine, dichloromethane, and dichloromethane containing α-bromoisobutyl bromide is 3:150:50.
[0031] Furthermore, the volume ratio of α-bromoisobutyl bromide to dichloromethane in the dichloromethane containing α-bromoisobutyl bromide is 2.6:50.
[0032] Furthermore, in the step S2, the dripping time of dichloromethane containing α-bromoisobutyl bromide needs to be controlled within 2 hours.
[0033] Furthermore, in step S2, the static reaction time is 19h-20h.
[0034] Furthermore, in step S2, the process of returning the mixed solution to room temperature can be stirred with nitrogen.
[0035] Furthermore, in step S2, washing is performed using a mixed solution of ethyl acetate and hexane, wherein the volume ratio of ethyl acetate to hexane is 1:1.
[0036] Furthermore, in step S2, the concentration method includes: dissolving the washed target substance with dichloromethane, and evaporating the solvent for concentration.
[0037] Those skilled in the art should understand that concentration can improve the purification effect. Therefore, in the present invention, there is no strict restriction on the concentration after concentration, and those skilled in the art can adjust it according to actual conditions.
[0038] Furthermore, in step S2, purification is performed by column chromatography using a mixture of ethyl acetate and n-hexane, wherein the volume ratio of ethyl acetate to n-hexane is 2-35:100.
[0039] Furthermore, in step S3, after the compound 2, N-(2-hydroxyethyl)maleimide and chloroform are mixed, the mass concentration of the compound 2 is 4.15 g / 4 mL.
[0040] Furthermore, in step S3, after the compound 2, N-(2-hydroxyethyl)maleimide and chloroform are mixed, the mass concentration of N-(2-hydroxyethyl)maleimide is 3.51 g / 4 mL.
[0041] Furthermore, in step S3, the reaction temperature is 50° C. and the reaction time is 13 h-15 h.
[0042] Furthermore, in step S3, during the reaction, those skilled in the art may stir the mixture to ensure sufficient reaction.
[0043] Furthermore, in step S3, the specific step of separating the target product includes: subjecting the reaction mixture to column chromatography using a mixture of methanol and dichloromethane, wherein the volume ratio of methanol to dichloromethane is 2-4:100.
[0044] Furthermore, the specific method for the esterification reaction between the linking factor and the polyglutamic acid in the polyglutamic acid polymer layer includes:
[0045] S1: Modifying polyglutamic acid: mixing polyglutamic acid, triethylamine and dichloromethane, cooling the mixed solution to 0°C after mixing; then dropping dichloromethane containing α-bromoisobutyl bromide, after the dropping is completed, returning the mixed solution to room temperature, standing for reaction, adding the reacted substance into ice water, filtering, washing, concentrating, and purifying to obtain polyglutamic acid modified with bromine;
[0046] S2: Mix the linking factor, triethylamine and dichloromethane, cool the mixed solution to 0°C, and then drop the bromine-modified polyglutamic acid solution to react. After the addition is completed, the mixed solution is returned to room temperature, solid-liquid separation, washing, drying, filtering, concentrating, and purification are performed to obtain an intermediate product.
[0047] Furthermore, in S1, after the polyglutamic acid, triethylamine and dichloromethane are mixed, the mass concentration of polyglutamic acid (PGlu) is 2.74 g / 153 mL.
[0048] Furthermore, in S1, the volume ratio of the triethylamine, dichloromethane, and dichloromethane containing α-bromoisobutyl bromide is 3:150:50.
[0049] Furthermore, in S1, the volume ratio of α-bromoisobutyl bromide to dichloromethane in the dichloromethane containing α-bromoisobutyl bromide is 2.6:50.
[0050] Furthermore, in S1, the dripping time of dichloromethane containing α-bromoisobutyl bromide needs to be controlled within 2 hours.
[0051] Furthermore, in S1, the static reaction time is 19h-20h.
[0052] Furthermore, in S1, the process of returning the mixed solution to room temperature can be stirred with nitrogen.
[0053] Furthermore, in S1, washing is performed using a mixed solution of ethyl acetate and hexane, wherein the volume ratio of ethyl acetate to hexane is 1:1.
[0054] Furthermore, in S1, the concentration method includes: dissolving the washed solid matter with dichloromethane, and evaporating the solvent for concentration.
[0055] Furthermore, in S1, purification is performed by column chromatography using a mixture of ethyl acetate and n-hexane, wherein the volume ratio of ethyl acetate to n-hexane is 2-35:100.
[0056] Furthermore, in S2, after the linking factor, triethylamine and dichloromethane are mixed, the mass concentration of the linking factor is 1.08 g / 50.39 mL.
[0057] Furthermore, in S2, the volume ratio of triethylamine to dichloromethane is 0.39:50.
[0058] Furthermore, in S2, the volume ratio of the bromine-modified polyglutamic acid solution to triethylamine is 0.33:0.39 by volume.
[0059] Furthermore, in S2, the method for preparing the bromine-modified polyglutamic acid solution specifically includes dissolving the bromine-modified polyglutamic acid in deionized water.
[0060] Furthermore, in S2, in the bromine-modified polyglutamic acid solution, the mass concentration of bromine-modified polyglutamic acid is 98 mg / mL-102 mg / mL.
[0061] Furthermore, in S2, the time for the reaction of dropping the bromine-modified polyglutamic acid solution is 19h-20h.
[0062] Furthermore, in S2, the specific method of washing includes: washing with ammonium chloride solution and saturated salt water in sequence.
[0063] Furthermore, in S2, the mass concentration of the ammonium chloride solution is 10%.
[0064] Furthermore, in S2, the specific method of drying includes: using sodium sulfate to adsorb and remove excess moisture on the surface of the target object.
[0065] Furthermore, in S2, the specific method of filtering includes: removing sodium sulfate from the dried product.
[0066] Furthermore, in S2, the concentration specifically includes: dissolving the filtered target substance with dichloromethane, and concentrating by evaporating the solvent.
[0067] Furthermore, in S2, the specific method of purification is purification by column chromatography, using a mixture of ethyl acetate and n-hexane, wherein the volume ratio of ethyl acetate to n-hexane is 35-55:100.
[0068] Furthermore, the specific method for the esterification reaction of the intermediate product with paclitaxel (PTX) includes:
[0069] The intermediate product, pyridine and dichloromethane are mixed, and the mixed solution is cooled to 0°C; then dichloromethane containing paclitaxel is added, and the mixed solution is restored to room temperature, reacted, solid-liquid separated, washed, dried, filtered, concentrated, purified, and a coating material is obtained.
[0070] Furthermore, after the intermediate product, pyridine and dichloromethane are mixed, the mass concentration of the intermediate product is 68.8 g / 25030 μL.
[0071] Furthermore, the volume ratio of pyridine to dichloromethane is 30:25000.
[0072] Furthermore, in the dichloromethane containing paclitaxel, the mass concentration of paclitaxel is 81 mg / 5 mL.
[0073] Furthermore, the volume ratio of the dichloromethane to the dichloromethane containing paclitaxel is 5:1.
[0074] Furthermore, the reaction time is 19h-21h.
[0075] Furthermore, stirring can be performed during the reaction to promote the reaction.
[0076] Furthermore, the specific method of washing includes washing with saturated salt water.
[0077] Furthermore, the specific method of drying includes: drying with sodium sulfate.
[0078] Furthermore, the filtering specifically includes: removing the dried sodium sulfate.
[0079] Furthermore, the concentration specifically includes: dissolving the filtered target substance with dichloromethane, and evaporating the solvent for concentration.
[0080] Furthermore, the specific method of purification is purification by column chromatography, using a mixture of ethyl acetate and n-hexane, wherein the volume ratio of ethyl acetate to n-hexane is 35-55:100.
[0081] The embodiments of the present invention have the following technical effects:
[0082] 1. The coating of the coated balloon of the present invention contains a polyglutamic acid polymer layer. In the polyglutamic acid polymer layer, polyglutamic acid not only has excellent mechanical properties and can adapt to the volume change of the balloon, but also has strong adhesion, so that after the balloon is filled with liquid, the polyglutamic acid polymer layer can still be stably attached to the surface of the balloon, so that the polyglutamic acid polymer layer can form a stable connection with the balloon; on this basis, the connecting factor forms an ester group with polyglutamic acid and paclitaxel, so that paclitaxel can be stably connected in the coating to prevent paclitaxel from being released prematurely. Applying the coating of the present invention to the surface of the balloon can not only stably release paclitaxel on the one hand, but also achieve a therapeutic effect on the vascular wall tissue, and on the other hand, overcome the technical difficulties in the prior art, achieve a stable connection between the coating and the balloon, so that the coated balloon of the present invention can be accurately administered, and can fully improve the narrow blood vessels, thereby helping to improve the therapeutic effect.
[0083] 2. The preparation method of the present invention is simple, and the stress-responsive controlled-release drug-coated balloon can be prepared through simple organic synthesis and solution immersion coating, which has low cost and is easy to preserve. BRIEF DESCRIPTION OF THE DRAWINGS
[0084] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0085] Figure 1 It is a flow chart of the preparation of the coating material provided in the embodiment of the present invention.
[0086] Figure 2 This is a diagram showing the effect of the coated balloon provided in Comparative Example 1 of the present invention after treating vascular stenosis.
[0087] Figure 3 This is a diagram showing the effect of the coated balloon provided in Example 1 of the present invention in treating vascular stenosis.
[0088] Figure 4 This is a graph showing the release process of paclitaxel in the coating of Example 1 of the present invention. DETAILED DESCRIPTION
[0089] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work belong to the scope of protection of the present invention.
[0090] In a first aspect, some embodiments of the present invention provide a coated balloon, wherein a coating is loaded on the surface of the balloon, wherein the coating includes a polyglutamic acid polymer layer, and a linking factor connects paclitaxel to the polyglutamic acid polymer layer;
[0091] The structural formula of the linking factor is as follows:
[0092] , where Br is bromine, O is oxygen, H is hydrogen, N is nitrogen, and OH is hydroxyl;
[0093] The polyglutamic acid polymer layer is connected to the surface of the balloon.
[0094] In some embodiments, the polyglutamic acid polymer layer includes polyglutamic acid, and the linking factor and the polyglutamic acid form an ester group, so that the linking factor is connected to the polyglutamic acid polymer layer;
[0095] The linker and paclitaxel form an ester group, so that the linker is linked to paclitaxel.
[0096] In a second aspect, some embodiments of the present invention further provide a method for preparing the coated balloon, the method comprising:
[0097] A connecting factor is prepared, the connecting factor undergoes an esterification reaction with polyglutamic acid in a polyglutamic acid polymer layer to obtain an intermediate product, the intermediate product undergoes an esterification reaction with paclitaxel to obtain a coating substance (PGlu-FC-PTX), the coating substance is dissolved to obtain a coating solution, the balloon is immersed in the coating solution at least once, and heat-treated to obtain a coated balloon (PGlu-FC-PTX@CB).
[0098] In some embodiments, the mass concentration of the coating material in the coating solution is 10%.
[0099] In some embodiments, the method for preparing the coating solution includes dispersing the coating material in physiological saline.
[0100] In some embodiments, the heat treatment temperature is 45° C.-55° C., and the heat treatment time is 50 min-70 min.
[0101] In some embodiments, the soaking time is 50s-70s.
[0102] In some embodiments, the balloon is immersed in the coating solution twice, the first immersion time is 50s-70s, and the second immersion time is 10s-20s, and heat treatment is performed after each immersion.
[0103] In the present invention, the thickness of the coating is controlled by the immersion time, so that the coating can not only be stably attached to the surface of the balloon, but also be conducive to the paclitaxel in the coating to fully improve the blood vessel wall.
[0104] In some embodiments, the preparation method of the ligation factor comprises:
[0105] Step S1: 5-(Hydroxymethyl)furan-2-acetaldehyde and diethyl ether are mixed, and the solution is cooled to -30°C after mixing, and 3M diethyl ether solution of methyl magnesium bromide is added, and the mixture is heated to room temperature for reaction, and the mixture is cooled to 0°C, and ammonium chloride solution is added for quenching to obtain compound 1;
[0106] Step S2: Compound 1, triethylamine and dichloromethane are mixed, and the mixed solution is cooled to 0°C after mixing; dichloromethane containing α-bromoisobutyl bromide is then added dropwise, and after the addition is completed, the mixed solution is returned to room temperature and allowed to stand for reaction, and the reacted substance is added to ice water, filtered, washed, concentrated, and purified to obtain Compound 2;
[0107] Step S3: Compound 2, N-(2-hydroxyethyl)maleimide and chloroform are mixed and reacted to separate the target product to obtain a linking factor.
[0108] In some embodiments, after the 5-(hydroxymethyl)furan-2-acetaldehyde and diethyl ether are mixed, the mass concentration of 5-(hydroxymethyl)furan-2-acetaldehyde is 6.92 g / 300 mL.
[0109] In some embodiments, the volume ratio of the methyl magnesium bromide, 3M ether solution, ether, and ammonium chloride solution is 42:300:200 by volume.
[0110] In some embodiments, the mass concentration of the ammonium chloride solution is 9%-11%.
[0111] In some embodiments, the method for preparing the ammonium chloride solution includes dispersing ammonium chloride in deionized water.
[0112] In some embodiments, the reaction time in step S1 is 11 h-13 h.
[0113] In some embodiments, the room temperature is 18°C-26°C.
[0114] In some embodiments, in step S1, stirring may be used during the reaction process to promote a full reaction between the substances.
[0115] In some embodiments, in step S2, after the compound 1, triethylamine and dichloromethane are mixed, the mass concentration of the compound 1 is 2.74 g / 153 mL.
[0116] In some embodiments, in step S2, the volume ratio of triethylamine, dichloromethane, and dichloromethane containing α-bromoisobutyl bromide is 3:150:50.
[0117] In some embodiments, the volume ratio of α-bromoisobutyl bromide to dichloromethane in the dichloromethane containing α-bromoisobutyl bromide is 2.6:50.
[0118] In some embodiments, in step S2, the dripping time of dichloromethane containing α-bromoisobutyl bromide needs to be controlled within 2 hours.
[0119] In some embodiments, in step S2, the reaction is allowed to stand for 19 hours to 20 hours.
[0120] In some embodiments, in step S2, the process of returning the mixed solution to room temperature can be stirred using nitrogen.
[0121] In some embodiments, in step S2, washing is performed using a mixed solution of ethyl acetate and hexane, wherein the volume ratio of ethyl acetate to hexane is 1:1.
[0122] In some embodiments, in step S2, the concentration method includes: dissolving the washed target substance with dichloromethane, and evaporating the solvent for concentration.
[0123] Those skilled in the art should understand that concentration can improve the purification effect. Therefore, in the present invention, there is no strict restriction on the concentration after concentration, and those skilled in the art can adjust it according to actual conditions.
[0124] In some embodiments, in step S2, purification is performed by column chromatography using a mixture of ethyl acetate and n-hexane, wherein the volume ratio of ethyl acetate to n-hexane is 2-35:100.
[0125] In some embodiments, in step S3, after the compound 2, N-(2-hydroxyethyl)maleimide and chloroform are mixed, the mass concentration of the compound 2 is 4.15 g / 4 mL.
[0126] In some embodiments, in step S3, after the compound 2, N-(2-hydroxyethyl)maleimide and chloroform are mixed, the mass concentration of N-(2-hydroxyethyl)maleimide is 3.51 g / 4 mL.
[0127] In some embodiments, in step S3, the reaction temperature is 50° C., and the reaction time is 13 h-15 h.
[0128] In some embodiments, during the reaction in step S3, a person skilled in the art may stir the mixture to ensure sufficient reaction.
[0129] In some embodiments, in step S3, the specific step of separating the target substance includes: subjecting the reaction mixture to column chromatography using a mixture of methanol and dichloromethane, wherein the volume ratio of methanol to dichloromethane is 2-4:100.
[0130] In some embodiments, the specific method for the esterification reaction between the linking factor and the polyglutamic acid in the polyglutamic acid polymer layer includes:
[0131] S1: Modifying polyglutamic acid: mixing polyglutamic acid, triethylamine and dichloromethane, cooling the mixed solution to 0°C after mixing; then dropping dichloromethane containing α-bromoisobutyl bromide, after the dropping is completed, returning the mixed solution to room temperature, standing for reaction, adding the reacted substance into ice water, filtering, washing, concentrating, and purifying to obtain polyglutamic acid modified with bromine;
[0132] S2: Mix the linking factor, triethylamine and dichloromethane, cool the mixed solution to 0°C, and then drop the bromine-modified polyglutamic acid solution to react. After the addition is completed, the mixed solution is returned to room temperature, solid-liquid separation, washing, drying, filtering, concentrating, and purification are performed to obtain an intermediate product.
[0133] In some embodiments, in S1, after the polyglutamic acid, triethylamine and dichloromethane are mixed, the mass concentration of polyglutamic acid (PGlu) is 2.74 g / 153 mL.
[0134] In some embodiments, in S1, the volume ratio of triethylamine, dichloromethane, and dichloromethane containing α-bromoisobutyl bromide is 3:150:50.
[0135] In some embodiments, in said S1, the volume ratio of α-bromoisobutyl bromide to dichloromethane in said dichloromethane containing α-bromoisobutyl bromide is 2.6:50.
[0136] In some embodiments, in S1, the dripping time of dichloromethane containing α-bromoisobutyl bromide needs to be controlled within 2 hours.
[0137] In some embodiments, in S1, the static reaction time is 19h-20h.
[0138] In some embodiments, in S1, the process of returning the mixed solution to room temperature can be stirred using nitrogen.
[0139] In some embodiments, in S1, washing is performed using a mixed solution of ethyl acetate and hexane, wherein the volume ratio of ethyl acetate to hexane is 1:1.
[0140] In some embodiments, in S1, the concentration method includes: dissolving the washed solid matter with dichloromethane, and evaporating the solvent for concentration.
[0141] In some embodiments, in S1, purification is performed by column chromatography using a mixture of ethyl acetate and n-hexane, wherein the volume ratio of ethyl acetate to n-hexane is 2-35:100.
[0142] In some embodiments, in S2, after the linking factor, triethylamine and dichloromethane are mixed, the mass concentration of the linking factor is 1.08 g / 50.39 mL.
[0143] In some embodiments, in S2, the volume ratio of triethylamine to dichloromethane is 0.39:50.
[0144] In some embodiments, in S2, the volume ratio of the bromine-modified polyglutamic acid solution to triethylamine is 0.33:0.39.
[0145] In some embodiments, in S2, the method for preparing the bromine-modified polyglutamic acid solution specifically comprises dissolving the bromine-modified polyglutamic acid in deionized water.
[0146] In some embodiments, in said S2, in said bromine-modified polyglutamic acid solution, the mass concentration of bromine-modified polyglutamic acid is 98 mg / mL-102 mg / mL.
[0147] In some embodiments, in S2, the time for the reaction of adding the bromine-modified polyglutamic acid solution is 19 hours to 20 hours.
[0148] In some embodiments, in S2, the specific method of washing includes: washing with ammonium chloride solution and saturated salt water in sequence.
[0149] In some embodiments, in S2, the mass concentration of the ammonium chloride solution is 10%.
[0150] In some embodiments, in S2, the specific method of drying includes: using sodium sulfate to adsorb and remove excess moisture on the surface of the target object.
[0151] In some embodiments, in S2, the specific method of filtering includes: removing sodium sulfate from the dried product.
[0152] In some embodiments, in S2, the concentration specifically includes: dissolving the filtered target substance with dichloromethane, and concentrating by evaporating the solvent.
[0153] In some embodiments, in S2, the specific method of purification is purification by column chromatography, using a mixture of ethyl acetate and n-hexane, wherein the volume ratio of ethyl acetate to n-hexane is 35-55:100.
[0154] In some embodiments, the specific method for the esterification reaction of the intermediate product with paclitaxel (PTX) comprises:
[0155] The intermediate product, pyridine and dichloromethane are mixed, and the mixed solution is cooled to 0°C; then dichloromethane containing paclitaxel is added, and the mixed solution is restored to room temperature, reacted, solid-liquid separated, washed, dried, filtered, concentrated, purified, and a coating material is obtained.
[0156] In some embodiments, after the intermediate product, pyridine and dichloromethane are mixed, the mass concentration of the intermediate product is 68.8 g / 25030 μL.
[0157] In some embodiments, the volume ratio of pyridine to dichloromethane is 30:25000.
[0158] In some embodiments, the mass concentration of paclitaxel in the dichloromethane containing paclitaxel is 81 mg / 5 mL.
[0159] In some embodiments, the volume ratio of the dichloromethane to the dichloromethane containing paclitaxel is 5:1.
[0160] In some embodiments, the reaction time is 19h-21h.
[0161] In some embodiments, stirring may be performed during the reaction to promote the reaction.
[0162] In some embodiments, the specific method of washing includes washing with saturated salt water.
[0163] In some embodiments, the specific method of drying includes: drying with sodium sulfate.
[0164] In some embodiments, the filtering specifically includes: removing the dried sodium sulfate.
[0165] In some embodiments, the concentration specifically includes: dissolving the filtered target substance with dichloromethane, and concentrating by evaporating the solvent.
[0166] In some embodiments, the specific method of purification is purification by column chromatography using a mixture of ethyl acetate and n-hexane, wherein the volume ratio of ethyl acetate to n-hexane is 35-55:100.
[0167] Here are some specific embodiments:
[0168] Embodiment 1,
[0169] (1) Add 5-(hydroxymethyl)furan-2-acetaldehyde (6.92 g, 54.9 mmol) and diethyl ether (300 mL) to a 1 L round-bottom flask equipped with a stirring bar, cool the solution to -30°C, and then slowly add methylmagnesium bromide, 3M diethyl ether solution (42 mL, 130 mmol). Heat the mixture to room temperature, stir for 12 h, cool the reaction to 0°C, and add 10% ammonium chloride solution (200 mL) to quench, to obtain compound 1;
[0170] (2) Compound 1 (2.74 g, 19.3 mmol), triethylamine (3 mL, 21.6 mmol) and dichloromethane (150 mL) were added to a 500 mL three-necked flask equipped with a stirring bar and mixed. The mixture was cooled to 0°C in an ice bath, and then dichloromethane (50 mL) containing α-bromoisobutyl bromide (2.6 mL, 21 mmol) was added dropwise over 2 h. During nitrogen stirring, the solution returned to room temperature and was allowed to react for 20 h. The reacted material was added to ice water, and the reaction mixture was filtered through a silica gel plug and washed with ethyl acetate:hexane in a volume ratio of 1:1. The washed solid was dissolved in dichloromethane, concentrated, and purified by column chromatography (the volume ratio of ethyl acetate to n-hexane was 35:100) to obtain compound 2 (4.35 g, yield 77%).
[0171] (3) Compound 2 (4.15 g, 14.3 mmol) was mixed with N-(2-hydroxyethyl)maleimide (3.51 g, 24.9 mmol) and chloroform (4 mL) in a 20 mL vial and stirred at 50 °C for 14 h. The crude reaction mixture was separated by column chromatography (methanol and dichloromethane volume ratio of 3:100) to obtain the linking factor (2.19 g, yield 35%).
[0172] (4) A 500 mL three-necked flask was equipped with a stirring bar, and polyglutamic acid (2.74 g), triethylamine (3 mL, 21.6 mmol) and dichloromethane (150 mL) were added. The mixture was cooled to 0 °C in an ice bath, and then dichloromethane (50 mL) containing α-bromoisobutyl bromide (2.6 mL, 21 mmol) was added dropwise over 2 h. During nitrogen stirring, the solution returned to room temperature and then allowed to react for 20 h. The reacted material was added to ice water, and the reaction mixture was filtered through a silica gel plug, washed with ethyl acetate:hexane in a volume ratio of 1:1, dissolved in dichloromethane, concentrated, and then purified by column chromatography (the volume ratio of ethyl acetate to n-hexane was 35:100) to obtain polyglutamic acid modified with bromine;
[0173] A linking factor (1.08 g, 2.50 mmol), triethylamine (0.39 mL, 2.8 mmol) and dichloromethane (50 mL) were added to a three-necked round-bottom flask equipped with a stirring bar. The solution was cooled to 0°C in an ice bath, and then a bromine-modified polyglutamic acid solution (0.33 mL, 100 mg / mL) was added dropwise to react for 20 h. After the addition was completed, the mixed solution was restored to room temperature, solid-liquid separation was performed, and the reaction mixture was washed with ammonium chloride solution (100 mL) and saturated brine (100 mL), dried over sodium sulfide, filtered sodium sulfide, and concentrated under reduced pressure. The crude product was purified by column chromatography (the volume ratio of ethyl acetate to n-hexane was 40:100) to obtain an intermediate product (1.07 g, yield 74%).
[0174] (5) The intermediate product (68.8 mg, 0.118 mmol), pyridine (30 μL, 0.372 mmol) and dichloromethane (25 mL) were added to a double-necked round-bottom flask equipped with a stirring bar. The solution was cooled to 0°C in an ice bath, and then dichloromethane (5 mL) with paclitaxel (81 mg, 0.339 mmol) was added dropwise. The reaction was slowly heated to room temperature and stirred for 20 hours. The reaction mixture was washed with saturated brine, dried over sodium sulfide, the sodium sulfide was filtered, concentrated, and the crude product was purified by column chromatography (the volume ratio of ethyl acetate and n-hexane was 40:100) to obtain a coating material (76 mg, yield 82%), as shown in FIG. Figure 1 shown.
[0175] (6) The coating material was dissolved to obtain a coating solution with a mass concentration of 10%. The experiment used an angioplasty balloon catheter with a diameter of 2 mm and a length of 20 mm, and the balloon was filled with normal saline. The balloon filled with normal saline was soaked in the prepared coating solution for 1 min, then moved into an oven and heat treated in air at 50°C for 1 h. The balloon was taken out and soaked in the coating solution again for 15 s, and heat treated in air at 50°C for 1 h to obtain a coated balloon.
[0176] Comparative Example 1:
[0177] The drug-coated balloon of Comparative Example 1 includes a drug balloon and a coating of the drug balloon;
[0178] The raw materials of the drug balloon coating are: paclitaxel 8g, iopromide 2g, ethanol 5g;
[0179] The preparation method of the coating of the drug balloon is:
[0180] (1) Take selected weights of paclitaxel, iopromide and ethanol, mix them evenly, heat to 30° C., and stir at constant temperature for 30 minutes to obtain a coating solution for later use;
[0181] (2) filling the drug balloon with saline;
[0182] (3) The coating solution is injected into the coating machine, and the power of the ultrasonic device of the coating machine is adjusted to 20 W. The drug balloon performs linear axial motion at 2 mm / s and circular axial motion at 3 rpm. The atomized coating solution is sprayed on the surface of the drug balloon to obtain the coating of the drug balloon.
[0183] The cumulative drug release content in Test Example 1 was tested over time. Example 1 was placed in 5 mL of aqueous solution to test the change in paclitaxel concentration in the aqueous solution over time. When the concentration of paclitaxel released in the aqueous solution was greater than 16 mg / mL, it indicated that the paclitaxel was completely released.
[0184] Example 1 and Comparative Example 1 were also applied to animal experiments to test the improvement of the blood vessels of the animals after the blood vessels of the animals were treated by Example 1 and Comparative Example 1.
[0185] Results and analysis:
[0186] It can be found that by the method of the present invention, Figure 1 The coating layer of the present invention is obtained by a chemical synthesis process. Figure 4 It can be found that the balloon coating layer obtained by the present invention can complete the drug release process within 90S. Figure 2 and Figure 3 By comparison, it was found that Figure 2 The results of the balloon treatment of the blood vessels of animals are shown below. Figure 3 This is the result of the balloon of the present invention treating the blood vessels of animals. Comparison shows that the diameter of the blood vessels after treatment in Comparative Example 1 is 1.71 mm, while the diameter of the blood vessels after treatment in Example 1 is 3.5 mm. It can be seen that the coated balloon of Example 1 of the present invention has a more significant improvement on the blood vessels. This is mainly because the coating of the present invention can be tightly connected to the balloon, which is conducive to the full contact between the balloon and the blood vessel wall, thereby facilitating the accurate administration of the coated balloon, and the therapeutic drugs in the present invention can be stably connected to the coating to prevent the premature loss of the drugs, so that the drugs can accurately act on the action site, so that the vascular stenosis can be effectively treated, so that the blood vessels improved by the balloon can maintain a patency state.
[0187] exist Figure 4 It can also be found that the paclitaxel in Example 1 of the present invention can be completely released within 90 seconds, which is conducive to the rapid absorption of the therapeutic drug.
[0188] It should be noted that the terms used in the present invention are only for describing specific embodiments, rather than limiting the scope of the present application. As shown in the present specification, unless the context clearly indicates an exception, the words "one", "a", "a kind of" and / or "the" do not specifically refer to the singular, but may also include the plural. The terms "include", "comprise" or any other variant thereof are intended to cover non-exclusive inclusion, so that the process, method or device including a series of elements includes not only those elements, but also includes other elements not explicitly listed, or also includes elements inherent to such process, method or device. In the absence of more restrictions, the elements defined by the sentence "include one..." do not exclude the presence of other identical elements in the process, method or device including the elements.
[0189] It should also be noted that the terms "center", "up", "down", "left", "right", "vertical", "horizontal", "inside", "outside", etc., indicating the orientation or positional relationship, are based on the orientation or positional relationship shown in the drawings, and are only for the convenience of describing the present invention and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as a limitation on the present invention. Unless otherwise clearly specified and limited, the terms "installed", "connected", "connected", etc. should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or it can be an indirect connection through an intermediate medium, or it can be a connection between the two elements. For those of ordinary skill in the art, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.
[0190] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the technical solutions of the embodiments of the present invention.
Claims
1. A method for preparing a coated balloon, characterized in that: The preparation method comprises: preparing a linking factor, allowing the linking factor to undergo an esterification reaction with polyglutamic acid in the polyglutamic acid polymer layer to obtain an intermediate product, allowing the intermediate product to undergo an esterification reaction with paclitaxel to obtain a coating substance, dissolving the coating substance to obtain a coating solution, immersing the balloon in the coating solution at least once, and performing a heat treatment to obtain a coated balloon; The preparation method of the connecting factor comprises: Step S1: 5-(Hydroxymethyl)furan-2-acetaldehyde and diethyl ether are mixed, and the solution is cooled to -30°C after mixing, and 3M diethyl ether solution of methyl magnesium bromide is added, and the mixture is heated to room temperature for reaction, and the mixture is cooled to 0°C, and ammonium chloride solution is added for quenching to obtain compound 1; Step S2: Compound 1, triethylamine and dichloromethane are mixed, and the mixed solution is cooled to 0°C after mixing; dichloromethane containing α-bromoisobutyl bromide is then added dropwise, and after the addition is completed, the mixed solution is returned to room temperature and allowed to stand for reaction, and the reacted substance is added to ice water, filtered, washed, concentrated, and purified to obtain Compound 2; Step S3: Compound 2, N-(2-hydroxyethyl)maleimide and chloroform are mixed and reacted to separate the target product to obtain a linking factor; The specific method for the esterification reaction between the linking factor and the polyglutamic acid in the polyglutamic acid polymer layer includes: S1: Modifying polyglutamic acid: mixing polyglutamic acid, triethylamine and dichloromethane, cooling the mixed solution to 0°C after mixing; then dropping dichloromethane containing α-bromoisobutyl bromide, after the dropping is completed, returning the mixed solution to room temperature, standing for reaction, adding the reacted substance into ice water, filtering, washing, concentrating, and purifying to obtain polyglutamic acid modified with bromine; S2: Mix the linking factor, triethylamine and dichloromethane, cool the mixed solution to 0°C, then drop the bromine-modified polyglutamic acid solution to react, and after the dropwise addition, return the mixed solution to room temperature, separate the solid and liquid, wash, dry, filter, concentrate, and purify to obtain an intermediate product; The specific method for the esterification reaction between the intermediate product and paclitaxel includes: The intermediate product, pyridine and dichloromethane are mixed, and the mixed solution is cooled to 0°C; then dichloromethane containing paclitaxel is added, and the mixed solution is restored to room temperature, reacted, solid-liquid separated, washed, dried, filtered, concentrated, purified, and a coating material is obtained.
2. The preparation method according to claim 1, characterized in that: The mass concentration of the coating substance in the coating solution is 10%; The heat treatment temperature is 45°C-55°C, and the heat treatment time is 50min-70min; The soaking time is 50s-70s.
3. The preparation method according to claim 1, characterized in that: In the step S1, after the 5-(hydroxymethyl)furan-2-acetaldehyde and diethyl ether are mixed, the mass concentration of 5-(hydroxymethyl)furan-2-acetaldehyde is 6.92 g / 300 mL; In terms of volume, the volume ratio of the methyl magnesium bromide, 3M ether solution, ether, and ammonium chloride solution is 42:300:200; The mass concentration of the ammonium chloride solution is 9%-11%; The reaction time in step S1 is 11 h-13 h.
4. The preparation method according to claim 1, characterized in that: In the step S2, after the compound 1, triethylamine and dichloromethane are mixed, the mass concentration of the compound 1 is 2.74 g / 153 mL; In the step S2, the volume ratio of triethylamine, dichloromethane, and dichloromethane containing α-bromoisobutyl bromide is 3:150:50; The volume ratio of α-bromoisobutyl bromide to dichloromethane in the dichloromethane containing α-bromoisobutyl bromide is 2.6:50; In the step S2, the dichloromethane containing α-bromoisobutyl bromide is added dropwise and the addition time needs to be controlled within 2 hours; In step S2, the reaction time is 19h-20h; In the step S2, washing is performed using a mixed solution of ethyl acetate and hexane, wherein the volume ratio of ethyl acetate to hexane is 1:1; In the step S2, purification is performed by column chromatography using a mixture of ethyl acetate and n-hexane, wherein the volume ratio of ethyl acetate to n-hexane is 2-35:100; In the step S3, after the compound 2, N-(2-hydroxyethyl)maleimide and chloroform are mixed, the mass concentration of the compound 2 is 4.15 g / 4 mL; In the step S3, after the compound 2, N-(2-hydroxyethyl)maleimide and chloroform are mixed, the mass concentration of N-(2-hydroxyethyl)maleimide is 3.51 g / 4 mL; In step S3, the reaction temperature is 50°C and the reaction time is 13h-15h; In step S3, the specific step of separating the target product includes: subjecting the reaction mixture to column chromatography using a mixture of methanol and dichloromethane, wherein the volume ratio of methanol to dichloromethane is 2-4:
100.
5. The preparation method according to claim 1, characterized in that: In S1, after polyglutamic acid, triethylamine and dichloromethane are mixed, the mass concentration of polyglutamic acid is 2.74 g / 153 mL; In S1, the volume ratio of triethylamine, dichloromethane, and dichloromethane containing α-bromoisobutyl bromide is 3:150:50; In S1, the volume ratio of α-bromoisobutyl bromide to dichloromethane in the dichloromethane containing α-bromoisobutyl bromide is 2.6:50; In S1, the dropwise addition of dichloromethane containing α-bromoisobutyl bromide needs to be controlled within 2 hours; In S1, the static reaction time is 19h-20h; In S1, washing is performed using a mixed solution of ethyl acetate and hexane, wherein the volume ratio of ethyl acetate to hexane is 1:1; In S1, purification is performed by column chromatography using a mixture of ethyl acetate and n-hexane, wherein the volume ratio of ethyl acetate to n-hexane is 2-35:100; In S2, after the linking factor, triethylamine and dichloromethane are mixed, the mass concentration of the linking factor is 1.08 g / 50.39 mL; In S2, the volume ratio of triethylamine to dichloromethane is 0.39:50; In S2, the volume ratio of the bromine-modified polyglutamic acid solution to triethylamine is 0.33:0.39 by volume; In S2, in the bromine-modified polyglutamic acid solution, the mass concentration of bromine-modified polyglutamic acid is 98 mg / mL-102 mg / mL; In S2, the time for the reaction of adding the bromine-modified polyglutamic acid solution dropwise is 19h-20h; The specific method of washing comprises: washing with ammonium chloride solution and saturated salt water in sequence; In S2, the mass concentration of the ammonium chloride solution is 10%; In S2, the specific method of purification is purification by column chromatography, using a mixture of ethyl acetate and n-hexane, wherein the volume ratio of ethyl acetate to n-hexane is 35-55:
100.
6. The preparation method according to claim 1, characterized in that: After the intermediate product, pyridine and dichloromethane are mixed, the mass concentration of the intermediate product is 68.8 g / 25030 μL; The volume ratio of pyridine to dichloromethane is 30:25000; In the dichloromethane containing paclitaxel, the mass concentration of paclitaxel is 81 mg / 5 mL; The volume ratio of the dichloromethane to the dichloromethane containing paclitaxel is 5:1; The reaction time is 19h-21h; The specific method of washing includes washing with saturated salt water; The specific method of purification adopts column chromatography for purification, and adopts a mixture of ethyl acetate and n-hexane, wherein the volume ratio of ethyl acetate to n-hexane is 35-55:100.
